ID | 1141 |
Name of the vaccine | Prevnar |
Microbe | Bacteria |
Disease name | Pneumococcal |
Name of bacteria | Streptococcus pneumoniae |
Type of vaccine | Inactivated |
Nucleic acid content | DNA |
Age | 6 weeks and older |
Description of the vaccine | Pneumococcal 7-valent conjugate vaccine (PCV 7) [Diphtheria CRM197 Protein]. |
Name of the manufacturer | Wyeth Pharmaceuticals Inc. |
Name of the manufacturing country | Philadelphia |
Year of manufacture | 2000 |
Clinical Phase status | Approved |
Bacterial strain | Gram-positive, facultative anaerobic bacteria. |
Efficacy | 88.9% efficacy in intent-to-treat analysis for all pneumococcal serotypes (between 1995-1998). |
Vaccine formulation | Homogeneous, white suspension. |
Dosage | 0.5 ml dose.
For infants : three doses and fourth dose at 12-15 months, dosing interval is 4 to 8 weeks.
Previously unvaccinated children 7 months or older :
7-11 months of age - 3 doses
12-23 months of age - 2 doses
Greater than or equal to 24 months to 9 years - 1 dose |
Mechanism of action | Induces functional antibodies to all vaccine serotypes. |
Route of administration | Intramuscular |
Indications | Prevents invasive disease caused by S. pneumoniae due to capsular serotypes included in the vaccine (4, 6B, 9V, 14, 18C, 19F and 23F). Also indicated for protection against otitis media. |
Export | NA |
Approval | US FDA |
Adjuvant | Aluminium phosphate |
Repurposing | For otitis media also. |
Side effects of vaccine | Injection site dermatitis, urticaria and pruritus, lymphadenopathy localized to injection site, hypersensitivity reaction, crying, angioneurotic edema, erythema multiforme. |
Post vaccination | NA |
Dose type | Both |
Interspecies transfer | NA |
PubMed identifier | NA |
Clinical trial number | NA |
Reference | https://www.fda.gov/media/76076/download |
Other name | NA |
Additional Links | NA
|